CN112794881A - 一种抗肝癌十三肽nksgtysnddlsh及其制备方法 - Google Patents
一种抗肝癌十三肽nksgtysnddlsh及其制备方法 Download PDFInfo
- Publication number
- CN112794881A CN112794881A CN202110178552.1A CN202110178552A CN112794881A CN 112794881 A CN112794881 A CN 112794881A CN 202110178552 A CN202110178552 A CN 202110178552A CN 112794881 A CN112794881 A CN 112794881A
- Authority
- CN
- China
- Prior art keywords
- ser
- tridecapeptide
- asn
- liver cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 24
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 26
- 229920001184 polypeptide Polymers 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000011347 resin Substances 0.000 claims abstract description 12
- 229920005989 resin Polymers 0.000 claims abstract description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 230000005764 inhibitory process Effects 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 4
- -1 Asn amino acid Chemical class 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 4
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 230000001644 anti-hepatocarcinoma Effects 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 4
- 239000003560 cancer drug Substances 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 235000019232 alkannin Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种抗肝癌十三肽NKSGTYSNDDLSH及其制备方法,属于生物制药领域。本发明的目的是为了解决现有的抗肝癌药物效果不好的问题,所述十三肽的分子量为1437.42,氨基酸序列为:Asn‑Lys‑Ser‑Gly‑Thr‑Tyr‑Ser‑Asn‑Asp‑Asp‑Leu‑Ser‑His。所述方法具体为:采用Fmoc固相合成法合成多肽,选用高分子树脂,按照上述的氨基酸序列的特征,His的羟基和树脂相连,然后Ser的氨基和His的羧基缩水反应,处理后,再添加Leu,Leu的氨基和Ser的羧基反应,依次从右向左添加氨基酸,加好最后一个Asn氨基酸后,再切除树脂即得到目标多肽。本发明首次合成了该肽,并且采用MTT方法检测了合成多肽的体外肝癌细胞的增殖抑制活性,所述合成多肽具有一定的肝癌细胞抑制能力。
Description
技术领域
本发明属于生物制药领域,具体涉及一种抗肝癌十三肽NKSGTYSNDDLSH及其制备方法。
背景技术
随着经济的不断发展,人类对健康也越来越重视,然而,环境、饮食等方面问题的存在,导致癌症患者数量逐步提升。在国内癌症领域,肝癌占比极为显著。由于在发病初期症状不够鲜明,患者在此方面意识不高,这就导致在发现确诊以后往往处于肝癌晚期,无法借助于较好的方式来进行治疗。同时,在治疗后常常会出现复发、转移等方面的问题,导致患者健康受到严重影响。目前,主要的肝癌化疗药物有5-氟尿嘧啶(5-FU)、顺铂、紫草素等,然而这些药物有严重的副作用并且价格昂贵。现有癌症治疗方式的诸多缺点和对人体的伤害,使寻找一个既便宜又高效且副作用小的药物迫在眉睫。
具有抗癌特性的生物活性肽,由于具有毒副作用小,不产生耐药性,特异性强等优点,已成为癌症治疗研究领域的热点。生物活性肽作为一种蛋白质资源的利用方式,不仅具有易消化、吸收的营养特点,而且具有抗氧化、抗菌、抗癌、降血压和提高人体免疫力等生理功能。其相对分子质量在蛋白质和游离氨基酸之间,可避免游离氨基酸之间的吸收竞争,具有独特的吸收机制,更容易被机体吸收利用,已成为当前国际抗癌药物及具有抗癌活性的产品。
近年来,生物活性肽的生物活性越来越受到人们的关注。它在很多疾病的治疗中表现出广泛的生物学活性,比如炎症,新陈代谢疾病和癌症。多肽,除了具有特有营养价值外,还有其他的生物活性,其中包括抗癌作用。相比传统药物、多肽具有高亲和力、强特异性、低毒性和充足的组织渗透性。因此对具有抗肝癌活性而无毒副作用的生物活性肽的开发研究,具有很强的现实意义。
发明内容
本发明的目的是为了解决现有的抗肝癌药物效果不好的问题,提供一种抗肝癌十三肽NKSGTYSNDDLSH及其制备方法。
为实现上述目的,本发明采取的技术方案如下:
一种抗肝癌十三肽NKSGTYSNDDLSH,所述十三肽的分子量为1437.42,氨基酸序列为:Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His。
一种上述的抗肝癌十三肽NKSGTYSNDDLSH的制备方法,所述方法具体为:采用Fmoc固相合成法合成多肽,选用高分子树脂,按照氨基酸序列Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His的特征,His的羟基和树脂相连,然后Ser的氨基和His的羧基缩水反应,处理后,再添加Leu,Leu的氨基和Ser的羧基反应,依次从右向左添加氨基酸,加好最后一个Asn氨基酸后,再切除树脂即得到目标多肽。
本发明相对于现有技术的有益效果为:本发明首次合成了该肽,并且采用MTT方法检测了合成多肽的体外肝癌细胞的增殖抑制活性,所述合成多肽具有一定的肝癌细胞抑制能力。
附图说明
图1为合成多肽Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His的HPLC图;
图2为合成多肽Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His的MS图;
图3为合成多肽Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His对肝癌细胞Hep3B的抑制活性柱状图。
具体实施方式
下面结合附图对本发明的技术方案作进一步的说明,但并不局限于此,凡是对本发明技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围,均应涵盖在本发明的保护范围中。
具体实施方式一:本实施方式记载的是一种抗肝癌十三肽NKSGTYSNDDLSH,所述十三肽的分子量为1437.42,氨基酸序列为:Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His。
具体实施方式二:具体实施方式一所述的一种抗肝癌十三肽NKSGTYSNDDLSH,所述十三肽用于人肝癌Hep3B细胞的体外抑制。
具体实施方式三:一种具体实施方式一或二所述的抗肝癌十三肽NKSGTYSNDDLSH的制备方法,所述方法具体为:采用Fmoc固相合成法合成多肽,选用高分子王氏树脂(西格玛公司),按照氨基酸序列Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His的特征,His的羟基和树脂相连,然后Ser的氨基和His的羧基缩水反应,处理后,再添加Leu,Leu的氨基和Ser的羧基反应,依次从右向左添加氨基酸,加好最后一个Asn氨基酸后,再切除树脂即得到目标多肽。
具体实施方式四:具体实施方式三所述的抗肝癌十三肽NKSGTYSNDDLSH的制备方法,所述方法还包括:采用高效液相色谱法进行纯化,色谱柱为岛津色谱柱,型号为ODS-SP(4.6*250mm*5um),流动相A:含有0.1%的三氟乙酸的水;流动相B:含有0.1%的三氟乙酸的乙腈;20min内B由3%上升到23%,流速1.0mL/min,检测波长214nm,液氮速冻,冷冻干燥,得到最后的产品,要求纯度达到98%以上,并经MS鉴定结构(如图1、2所示)。
具体实施方式五:具体实施方式四所述的抗肝癌十三肽NKSGTYSNDDLSH的制备方法,所述冷冻干燥的具体条件为:气压:180pa,温度:-50.5℃,时间:18h。
实施例1:
合成多肽体外抑制活性通过MTT比色法分析多肽对肝癌Hep3B细胞的生长抑制作用。具体操作步骤如下:选择处于对数生长期,生长状态良好的细胞,经胰蛋白酶消化后,培养液阻断消化,转移至离心管中,放入离心机1000×g,离心3min后,小心弃掉上清,加入培养液重悬,取血球计数板计数,根据计数结果,以每孔200uL的4×104个/mL细胞量接种96孔板,接种板过程注意动作轻柔,不要晃动96孔板,避免细胞聚集成团,不能均匀铺满孔底。37℃、5%CO2饱和湿度的培养箱中过夜培养。第二天,将96孔板内含10%FBS的培养液换成含1%FBS的培养液,放入恒温培养箱饥饿处理2h。这一步注意用蠕动泵吸掉培养液时应加倍小心不要接触到孔底,以免细胞被吸掉,影响实验准确性。以100uL,0.05、0.1、0.15、0.20、0.25mg/mL浓度的多肽处理细胞,对于每一个浓度,可设计8个复孔。需要设计空白调零孔,将操作时间控制为24h。上述操作结束后,在各个孔内添加20uL,5mg/mLMTT和新鲜完全培养基180uL,在37℃,5%的二氧化碳培养箱中持续培养2h。此时,在显微镜下能够看到甲瓒结晶。去除上清液以后,分别给各个孔内添加100uLDMSO,避光震荡10min,进而使得甲瓒结晶在DMSO中完全溶解,设置吸光度为490nm,对吸光值进行检测。每组试验重复3次,根据公式计算不同浓度处理后细胞存活率。细胞存活率=(A实验组-A空白调零孔)/(A对照组-A空白零孔)×100%,不同浓度,0.05、0.1、0.15、0.20、0.25mg/mL多肽处理肝癌Hep3B细胞后,细胞活力分别为98.62%,85.32%,79.21%,60.31%,45.25%(如图3所示)。
实施例2:
肝癌细胞Hep3B,200uL细胞悬液(4×104个/mL),加至96孔板中,于37℃恒温CO2培养箱中培养,24h后细胞贴壁,吸出废旧培养液,加入终体积为200uL的0.05mg/mL的多肽样品的新鲜培养基,并以完全培养基为阴性对照,于37℃恒温CO2培养箱中培养,24小时后吸出药液,用PBS洗版3次,加入20μL,5mg/mLMTT和新鲜完全培养基180uL,在37℃,5%的二氧化碳培养箱中持续培养2h。去除上清液以后,分别给各个孔内添加100μLDMSO,避光震荡10min,设置吸光度为490nm,对吸光值进行检测并计算抑制率。由图3可知,0.05mg/mL的多肽处理肝癌细胞Hep3B的细胞活力为98.62%。
Claims (5)
1.一种抗肝癌十三肽NKSGTYSNDDLSH,其特征在于:所述十三肽的分子量为1437.42,氨基酸序列为:Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His。
2.根据权利要求1所述的一种抗肝癌十三肽NKSGTYSNDDLSH,其特征在于:所述十三肽用于人肝癌Hep3B细胞的体外抑制。
3.一种权利要求1或2所述的抗肝癌十三肽NKSGTYSNDDLSH的制备方法,其特征在于:所述方法具体为:采用Fmoc固相合成法合成多肽,选用高分子树脂,按照氨基酸序列Asn-Lys-Ser-Gly-Thr-Tyr-Ser-Asn-Asp-Asp-Leu-Ser-His的特征,His的羟基和树脂相连,然后Ser的氨基和His的羧基缩水反应,处理后,再添加Leu,Leu的氨基和Ser的羧基反应,依次从右向左添加氨基酸,加好最后一个Asn氨基酸后,再切除树脂即得到目标多肽。
4.根据权利要求3所述的抗肝癌十三肽NKSGTYSNDDLSH的制备方法,其特征在于:所述方法还包括:采用高效液相色谱法进行纯化,色谱柱为岛津色谱柱,型号为ODS-SP(4.6*250mm*5um),流动相A:含有0.1%的三氟乙酸的水;流动相B:含有0.1%的三氟乙酸的乙腈;20min内B由3%上升到23%,流速1.0mL/min,检测波长214nm,液氮速冻,冷冻干燥,得到最后的产品,要求纯度达到98%以上。
5.根据权利要求4所述的抗肝癌十三肽NKSGTYSNDDLSH的制备方法,其特征在于:所述冷冻干燥的具体条件为:气压:180pa,温度:-50.5℃,时间:18h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110178552.1A CN112794881B (zh) | 2021-02-09 | 2021-02-09 | 一种抗肝癌十三肽nksgtysnddlsh及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110178552.1A CN112794881B (zh) | 2021-02-09 | 2021-02-09 | 一种抗肝癌十三肽nksgtysnddlsh及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112794881A true CN112794881A (zh) | 2021-05-14 |
CN112794881B CN112794881B (zh) | 2023-10-31 |
Family
ID=75814922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110178552.1A Active CN112794881B (zh) | 2021-02-09 | 2021-02-09 | 一种抗肝癌十三肽nksgtysnddlsh及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112794881B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2628006A1 (de) * | 1976-06-23 | 1977-12-29 | Max Planck Gesellschaft | Tridecapeptid mit gastrinwirkung |
CN105131089A (zh) * | 2015-09-28 | 2015-12-09 | 华南理工大学 | 一种十三肽及其应用 |
CN106084011A (zh) * | 2016-06-30 | 2016-11-09 | 华南理工大学 | 一种十二肽vpgtpknldspr及其应用 |
WO2018156892A1 (en) * | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
CN110100945A (zh) * | 2019-05-05 | 2019-08-09 | 黑龙江省科学院大庆分院 | 一种汉麻降血脂肽组合物及其应用 |
CN110724179A (zh) * | 2019-10-14 | 2020-01-24 | 陈勇 | 一种抗肿瘤多肽及其制备方法和用途 |
-
2021
- 2021-02-09 CN CN202110178552.1A patent/CN112794881B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2628006A1 (de) * | 1976-06-23 | 1977-12-29 | Max Planck Gesellschaft | Tridecapeptid mit gastrinwirkung |
CN105131089A (zh) * | 2015-09-28 | 2015-12-09 | 华南理工大学 | 一种十三肽及其应用 |
CN106084011A (zh) * | 2016-06-30 | 2016-11-09 | 华南理工大学 | 一种十二肽vpgtpknldspr及其应用 |
WO2018156892A1 (en) * | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
CN110100945A (zh) * | 2019-05-05 | 2019-08-09 | 黑龙江省科学院大庆分院 | 一种汉麻降血脂肽组合物及其应用 |
CN110724179A (zh) * | 2019-10-14 | 2020-01-24 | 陈勇 | 一种抗肿瘤多肽及其制备方法和用途 |
Non-Patent Citations (3)
Title |
---|
JOUNG-WOO CHOI等: "Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy", 《JOURNAL OF CONTROLLED RELEASE》 * |
宋淑敏等: "汉麻降脂肽氨基酸序列分析", 《中国粮油学报》 * |
魏连会等: "汉麻籽粕酶解物中抗肝癌Hep3B细胞活性肽的分离与鉴定", 《中国粮油学报》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112794881B (zh) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108715600B (zh) | 一种促进肠黏膜上皮细胞增殖和迁移的寡肽及其制备方法和应用 | |
CN105566452B (zh) | 一种具有环状结构的抗菌肽及其制备方法和应用 | |
CN108676073B (zh) | 一种抗肥胖十肽llvvypwtqr及其应用 | |
CN109439612B (zh) | 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途 | |
CN106699846B (zh) | 一种抗肥胖十一肽nalkcchscpa | |
CN115960261A (zh) | 色氨酸和苯丙氨酸跨链交互β-发卡抗菌肽WFL及其制备方法和应用 | |
CN107474117B (zh) | 一种抗肿瘤环肽及其制备方法和医药应用 | |
CN107337715B (zh) | 一种抗肿瘤环肽及其制备与应用 | |
CN106749524B (zh) | 一种抗肥胖七肽npvwkrk | |
CN111647044B (zh) | 一种富含苯丙氨酸抗菌肽及其制备方法和应用 | |
CN102558298A (zh) | 一种利用固相多肽合成法合成四肽异构体的方法及其应用 | |
CN109503701B (zh) | 一种环肽及其在制备抗肿瘤药物中的应用 | |
CN105237624B (zh) | 一种七肽emlqppl及其应用 | |
CN112794881A (zh) | 一种抗肝癌十三肽nksgtysnddlsh及其制备方法 | |
CN115819504B (zh) | 鲟鱼功能性多肽及其应用 | |
CN106518971A (zh) | 一种抗肥胖十肽canphelpnk | |
CN116789748A (zh) | 一种鲟鱼鱼鳔抗肺癌寡肽及其应用 | |
CN110283245A (zh) | 猪髓源pmap-23衍生抗菌肽及制备方法和应用 | |
CN113621054B (zh) | 一种具有抑制人结肠癌细胞(ht-29细胞)增殖作用的鸡源胶原肽及其制备与应用 | |
CN105131089A (zh) | 一种十三肽及其应用 | |
CN112430254B (zh) | 一种抗凝血活性肽衍生物及其制备方法和用途 | |
CN109081862A (zh) | 一种抗肥胖四肽pqtr及其应用 | |
CN106749533B (zh) | 一种抗肥胖十七肽lnnpsvcdcdcmmkaar | |
CN108101960B (zh) | 一种具有ace抑制活性和抗肿瘤的多肽分子及其制备方法 | |
CN116496355B (zh) | 一种耐盐防弧菌抗菌肽fh-18及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |